www.pfizer.com Open in urlscan Pro
172.64.144.149  Public Scan

Form analysis
1 forms found in the DOM

GET /news/press-release/press-release-detail/pfizer-completes-acquisition-seagen

<form class="views-exposed-form bef-exposed-form" data-bef-auto-submit-full-form="" data-bef-auto-submit="" data-bef-auto-submit-delay="500" data-drupal-selector="views-exposed-form-site-search-default-search"
  action="/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen" method="get" id="views-exposed-form-site-search-default-search" accept-charset="UTF-8" data-once="exposed-form bef-auto-submit cvJqueryValidate"
  novalidate="novalidate">
  <div class="js-form-item form-item js-form-type-textfield form-item-changed-after js-form-item-changed-after">
    <label for="edit-changed-after">Changed</label>
    <input data-bef-auto-submit-exclude="" class="bef-datepicker form-text hasDatepicker" autocomplete="off" data-drupal-selector="edit-changed-after" data-msg-maxlength="Changed field has a maximum length of 128." type="text" id="edit-changed-after"
      name="changed_after" value="" size="30" maxlength="128">
  </div>
  <div class="js-form-item form-item js-form-type-textfield form-item-changed-before js-form-item-changed-before">
    <label for="edit-changed-before">Changed</label>
    <input data-bef-auto-submit-exclude="" class="bef-datepicker form-text hasDatepicker" autocomplete="off" data-drupal-selector="edit-changed-before" data-msg-maxlength="Changed field has a maximum length of 128." type="text"
      id="edit-changed-before" name="changed_before" value="" size="30" maxlength="128">
  </div>
  <div class="DJ__searchForm__processed search__form medium-7 lmedium-6">
    <div class="js-form-item form-item js-form-type-search-api-autocomplete form-item-search-api-fulltext js-form-item-search-api-fulltext form-no-label">
      <label for="edit-search-api-fulltext" class="visually-hidden">How can we help you?</label>
      <input placeholder="How can we help you?" data-bef-auto-submit-exclude="" data-drupal-selector="edit-search-api-fulltext" data-search-api-autocomplete-search="site_search" class="form-autocomplete form-text ui-autocomplete-input"
        data-autocomplete-path="/search_api_autocomplete/site_search?display=default_search&amp;&amp;filter=search_api_fulltext" data-msg-maxlength="How can we help you? field has a maximum length of 128." type="text" id="edit-search-api-fulltext"
        name="search_api_fulltext" value="" size="30" maxlength="128" data-once="autocomplete search-api-autocomplete" autocomplete="off" title="Search Input Box" aria-label="Search Input Box">
      <div id="predict-search-suggestion"></div>
    </div>
    <div data-drupal-selector="edit-input-wrappers"></div>
    <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions">
      <div class="btn btn--primary btn--round disabled">
        <input data-bef-auto-submit-click="" data-twig-suggestion="site_search_input" data-drupal-selector="edit-submit-site-search" type="submit" id="edit-submit-site-search" value="Search" class="button js-form-submit form-submit"
          title="Search Button" data-pfa-listener-click="1">
        <svg viewBox="0 0 100 100" class="icon">
          <use xlink:href="/profiles/pfecpfizercomus_profile/themes/pfcorporate_helix/public/assets/sprites/symbol/svg/sprite.symbol.svg#arrow-right"></use>
        </svg>
      </div>
    </div>
  </div>
  <div class="result-counter hidden"><b>4843</b> search results for</div>
  <div class="grid-x">
    <div class="cell small-12 medium-6">
      <div class="suggestions-list-container autocomplete-wrapper" data-drupal-selector="edit-autocomplete-wrapper">
        <div class="description hide" data-drupal-selector="edit-description">Suggestions within Pfizer.com</div>
        <ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front search-api-autocomplete-search" unselectable="on" style="display: none;"></ul>
      </div>
    </div>
  </div>
</form>

Text Content

Skip to main content

 * Science
   Clinical Trials
   * Guide to Clinical Trials Your participation makes a difference
   * Clinical Trials in Children Designed to improve kids' health
   * Data and Results Sharing our Results
   * Integrity and Transparency Building Trust
   * Diversity Equity and Representation
   * Plain Language Study Results Trial Result Summaries
   * Expanded Access & Compassionate Use Possible Treatment Options
   Find a TrialAreas of Focus
   * Rare Disease Smaller populations but big impact
   * Internal Medicine Extending lifespans worldwide
   * Inflammation & Immunology Treatment at the molecular level
   * Vaccines Preventing the spread of infections
   * Oncology The science of optimism
   * Anti Infectives Combatting an evolving risk
   Areas of Innovation
   * Gene Therapy Breakthroughs become treatments
   * Medicinal Sciences The next generation of science
   * Precision Medicine Developing tailored medicines
   * Maternal Immunization Protecting newborns at the start
   * mRNA Technology Unleashing the next wave of scientific innovations
   Diseases & ConditionsCoronavirus ResourcesProduct PipelineResearch Sites
 * Products
   How Drugs are Made
   * Branded vs. Generic Learn the difference
   * Biologics & Biosimilars Cures found in nature
   * Commitment to Quality Maintaining the highest standards
   * Global Supply Strategic manufacturing locations
   * Manufacturing Sites Where medicine is made in the U.S.
   Medicine Safety
   * Health Literacy Learning to be well
   * Treatment Choices Learning about treatment decisions
   * Partnering With Patients Helping others by reporting side effects
   * Tips for Patients Preventing medication errors
   * Reporting Adverse Events
   * Counterfeiting Preventing medication errors
   * Product Safety
   Product ListProduct ContactsPfizerPro for ProfessionalsPatient Assistance
   ProgramsDistributors
   * Pfizer Distributors
 * Stories
   ArticlesAnnouncementsBehind the Science FeaturesPodcastseBooks
 * Newsroom
   Press ReleasesMedia Asset LibraryUpdates and StatementsPartnering NewsMedia
   Contacts
 * About
   People
   * Executives Our senior-most leadership
   * Board Members The people steering our company
   * Scientists Our experts making discoveries
   * Patient Stories Our patients
   * Colleague Stories Our colleagues
   Responsibility
   * Ethics & Compliance Each of us is responsible
   * Diversity, Equity, and Inclusion Everyone has something to offer
   * EHS Governance
   * Environmental Sustainability Our responsiblity to the environment
   * Global Impact Meeting urgent needs worldwide
   * Health & Safety
   * Human Rights Furthering dignity and worth
   * Intellectual Property The benefits of fair competition
   * Patient Advocacy & Engagement Putting Patients First
   * Misinformation
   Programs & Policies
   * Grants Support for independent research
   * Political Partnership Supporting like-minded organizations
   * Working with Healthcare Professionals Collaboration to improve lives
   * Prescription Value & Pricing How to lower patient costs
   * Privacy Principles Commitment to personal data privacy
   * Ready for Cures Improving Access to Medicines
   * Transparency in Grants Committed to Disclosure
   Investors
   * Investors Overview Information for stockholders
   * Why Invest Why to join us in our mission
   * Events & Presentations Calendar of upcoming events
   * Financial Reports Quarterly reports and more
   * Investor News Announcements about our performance
   * Stock Information Charts and data
   * Shareholder Services Information on stock transactions
   Corporate Governance
   * Corporate Governance Overview Gaining insight into our performance
   * Board Committees & Charters Defining the corporate structure
   * The Pfizer Board Policies Ensuring ethical leadership
   * Corporate Governance FAQs Learn more about our approach
   * Contact Our Directors Email any of our Directors
   PurposeHistoryCareersPartners
   * Research and Business Development Partnerships
   * Venture Investments
   * Business to Business
   * Pfizer CentreOne
   * Pfizer Ignite
   * Submit Your Opportunities


InvestorsCareersMediaPartners
Contact Us

 * Careers
 * Investors

Search
Contact Us

Hamburger
Changed
Changed
How can we help you?



4843 search results for
Suggestions within Pfizer.com

Header close

Header close



ARTICLE



Pfizer Press release
CorporateInvestments


PFIZER COMPLETES ACQUISITION OF SEAGEN

Thursday, December 14, 2023 - 07:39am
View pdfcopyCopy to clipboardOpen in tab
 * Further establishes Pfizer as a leading oncology company poised to accelerate
   the next generation of breakthrough treatments for people with cancer
 * To address U.S. Federal Trade Commission concerns, Pfizer has chosen to
   irrevocably donate the rights of royalties from sales of Bavencio® (avelumab)
   in the U.S. to the American Association for Cancer Research (AACR)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the
successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global
biotechnology company that discovers, develops and commercializes transformative
cancer medicines. Pfizer completed its acquisition of all outstanding common
stock of Seagen for $229 in cash per share, for a total enterprise value of
approximately $43 billion.

“Cancer remains a leading cause of death, and one in three people in the U.S.
will receive a cancer diagnosis in their lifetime. With one of the largest
investments in Pfizer’s history, we are going all in on cancer with the goal of
delivering breakthroughs that drastically improve the lives of people with
cancer,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.
“With Seagen’s proprietary, world-leading Antibody-Drug Conjugate (ADC)
technology, together with the scale and strength of Pfizer's capabilities and
expertise, we are poised to change the cancer treatment paradigm. We believe
Oncology will be a significant growth driver for Pfizer and contribute
meaningfully to the achievement of our near- and long-term financial goals.”

Seagen is a world-leader in ADC technology, a transformative modality that is
emerging as a powerful tool across a broad range of cancers designed to
preferentially kill cancer cells and limit off-target toxicities. With the
addition of Seagen’s four in-line medicines, ADCETRIS® (brentuximab vedotin),
PADCEV® (enfortumab vedotin), TIVDAK® (tisotumab vedotin) and TUKYSA®
(tucatinib), Pfizer’s industry-leading Oncology portfolio now includes over 25
approved medicines and biosimilars across more than 40 indications, including
nine medicines that are either blockbuster or have the potential to be
blockbuster.

With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with
60 programs spanning multiple modalities, including ADCs, small molecules,
bispecifics and other immunotherapies. Moving forward, Pfizer will leverage its
leading protein engineering and medicinal chemistry capabilities to advance
Seagen’s ADC technology, unlocking potential novel combinations and
next-generation biologics.

“This is a great day for Pfizer, and, more importantly, for people living with
cancer, as we bring together the game-changing science and top talent of Seagen
and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief
Oncology Officer and Executive Vice President, Pfizer. “Driven by science and a
passion for improving and extending patients’ lives, together, we will work with
urgency towards our common purpose to deliver transformative cancer medicines
and bring new hope to people living with cancer everywhere.”

As previously disclosed, to address U.S. Federal Trade Commission concerns,
Pfizer has chosen to irrevocably donate the rights of royalties from sales of
Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research
(AACR). This unrestricted donation will support AACR in its mission to prevent
and cure cancer through research, education, communication, collaboration,
science policy, and funding for cancer research.

Guggenheim Securities, LLC served as Pfizer’s financial advisor and Wachtell,
Lipton, Rosen & Katz and Arnold & Porter Kaye Scholer LLP served as Pfizer’s
legal advisors. Centerview Partners LLC served as Seagen’s financial advisor and
Sullivan & Cromwell LLP served as Seagen’s legal advisor. MTS Health Partners
also provided financial advice to Seagen.

Prescribing Information for Legacy Seagen Medicines 

Please see full Prescribing Information for ADCETRIS® (brentuximab vedotin).

Please see full Prescribing Information for PADCEV® (enfortumab vedotin).

Please see full Prescribing Information for TIVDAK® (tisotumab vedotin).

Please see full Prescribing Information for TUKYSA® (tucatinib).

About Pfizer Oncology

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our
industry-leading portfolio and extensive pipeline includes game-changing
mechanisms of action to attack cancer from multiple angles, including
antibody-drug conjugates (ADCs), small molecules, bispecifics and other
immunotherapies. We are focused on delivering transformative therapies in some
of the world’s most common cancers, including breast cancer, genitourinary
cancer and hematologic malignancies, as well as melanoma, gastrointestinal,
gynecological and thoracic cancers, which includes lung cancer. Driven by
science, we are committed to accelerating breakthroughs to extend and improve
patients’ lives.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products, including innovative medicines and
vaccines. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge the
most feared diseases of our time. Consistent with our responsibility as one of
the world's premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For more than 170
years, we have worked to make a difference for all who rely on us. We routinely
post information that may be important to investors on our website at
www.pfizer.com. In addition, to learn more, please visit us on and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.

Disclosure Notice: The information contained in this press release is as of
December 14, 2023. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information or future
events or developments.

This press release contains forward-looking information about, among other
topics, Pfizer’s acquisition of Seagen, Seagen’s ADC technology, Pfizer’s
Oncology portfolio and Seagen’s commercialized and pipeline products, including
their potential benefits, anticipated revenue contribution and growth and
potential blockbuster status, that involves substantial risks and uncertainties
that could cause actual results to differ materially from those expressed or
implied by such statements. Risks and uncertainties include, among other things,
risks related to the ability to realize the anticipated benefits of the
acquisition, including the possibility that the expected benefits from the
acquisition will not be realized or will not be realized within the expected
time period; the risk that the businesses will not be integrated successfully;
disruption from the transaction making it more difficult to maintain business
and operational relationships; negative effects of the consummation of the
acquisition on the market price of Pfizer’s common stock and/or operating
results; significant transaction costs; unknown liabilities; other business
effects and uncertainties and the uncertainties inherent in business and
financial planning, including the effects of industry, market, business,
economic, political or regulatory conditions; risks related to Pfizer’s business
and prospects, adverse developments in Pfizer’s markets, or adverse developments
in the U.S. or global capital markets, credit markets, regulatory environment or
economies generally; future exchange and interest rates; changes in tax and
other laws, regulations, rates and policies; future business combinations or
disposals; uncertainties regarding the commercial success of Pfizer’s and
Seagen’s commercialized and pipeline products; the uncertainties inherent in
research and development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for clinical trials, regulatory
submission dates, regulatory approval dates and/or launch dates, as well as the
possibility of unfavorable new clinical data and further analyses of existing
clinical data; risks associated with interim data; the risk that clinical trial
data are subject to differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with the design of
and results from the clinical studies; whether and when drug applications may be
filed in any jurisdictions for Pfizer’s or Seagen’s pipeline products; whether
and when any such applications may be approved by regulatory authorities, which
will depend on myriad factors, including making a determination as to whether
the product's benefits outweigh its known risks and determination of the
product's efficacy and, if approved, whether any such products will be
commercially successful; decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could affect the
availability or commercial potential of such products; uncertainties regarding
the impact of COVID-19; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022 and in its
subsequent reports on Form 10-Q, including in the sections thereof captioned
“Risk Factors” and “Forward-Looking Information and Factors That May Affect
Future Results”, as well as in its subsequent reports on Form 8-K, all of which
are filed with the U.S. Securities and Exchange Commission and available at
www.sec.govand www.pfizer.com.

All trademarks mentioned are the property of their respective owners.

Category: Corporate, Investments

 

View source version on businesswire.com:
https://www.businesswire.com/news/home/20231213759493/en/ 

Media Contact: 
+1 (212) 733-1226 
PfizerMediaRelations@Pfizer.com (link sends email)

Investor Contact: 
+1 (212) 733-4848 
IR@Pfizer.com(link sends email)

Source: Pfizer Inc.

Share





Sign up for the latest Pfizer Wire news alerts

Receive real-time updates on Pfizer’s news delivered directly to your inbox.

Our Pipeline: Potential Breakthroughs in the Making

We're elevating our breakthroughs in a bold new way. Check out our new
visualized product pipeline.

Pfizer Quarterly Corporate Performance

Our report for the Second Quarter of 2022.

Analyst Events & Presentations

Check out the latest events and presentations.

Corporate Fact Sheet

For more than 170 years, Pfizer has worked to make a difference for all who rely
on us.

Executive Leadership

Meet the executive leadership team, our senior-most leadership and
decision-making management body who focus on major financial, strategic, and
operational decisions for the entire company.

Sign up for the latest Pfizer Wire news alerts

Receive real-time updates on Pfizer’s news delivered directly to your inbox.

Our Pipeline: Potential Breakthroughs in the Making

We're elevating our breakthroughs in a bold new way. Check out our new
visualized product pipeline.

Pfizer Quarterly Corporate Performance

Our report for the Second Quarter of 2022.

Analyst Events & Presentations

Check out the latest events and presentations.

Corporate Fact Sheet

For more than 170 years, Pfizer has worked to make a difference for all who rely
on us.

Executive Leadership

Meet the executive leadership team, our senior-most leadership and
decision-making management body who focus on major financial, strategic, and
operational decisions for the entire company.


Button previous Button next


PFIZER WIRE

STAY UP TO DATE ON THE LATEST NEWS AND ALERTS THROUGH THE PFIZER WIRE

Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media
Relations team delivered directly to your inbox. 

 

Sign Up Now


 * INVESTORS

 * CAREERS

 * MEDIA

 * PARTNERS

 * Grant Seekers
 * Healthcare Professionals
 * Business to Business
 * Merchandise

 * Privacy Statement
 * Terms of Use
 * Contact Us



 * © 2023 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of
the United States.

The products discussed herein may have different labeling in different
countries.

 * Twitter
 * Facebook
 * Linked In
 * Instagram
 * Youtube


Cookies Preferences






WE CARE ABOUT YOUR PRIVACY

Pfizer uses cookies and similar technologies to enhance and personalize your
customer experience. By granting us permission, you enable Pfizer and our
analytics and marketing partners to collect, use, and share information about
your website interactions to tailor your digital experiences, our services, and
content for you. To learn more about how Pfizer uses these technologies, please
read ourPrivacy Policy
Cookies Preferences Decline All Accept All



WE CARE ABOUT YOUR PRIVACY

Cookies and similar technologies typically collect information about how you use
a website such as pages and content you view, information you submit, digital
tools you use, and links you click. Depending on your interactions with us, this
information may suggest certain details about your health.

ESSENTIAL COOKIES

Always Active


These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

 * FUNCTIONAL COOKIES
   
   Always Active
   
   These cookies enable the website to provide enhanced functionality and
   personalisation. They may be set by us or by third party providers whose
   services we have added to our pages. If you do not allow these cookies then
   some or all of these services may not function properly.

MARKETING COOKIES

Marketing Cookies


Marketing cookies help us share content with you that you may find interesting
and relevant.

ANALYTICS COOKIES

Analytics Cookies


Analytics cookies measure website use to learn what content is most useful to
users and to us help improve it.

Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Save and Accept Changes